Format

Send to

Choose Destination
Int J Biol Macromol. 2019 May 1;128:574-582. doi: 10.1016/j.ijbiomac.2019.01.195. Epub 2019 Jan 30.

Ribophorin II potentiates P-glycoprotein- and ABCG2-mediated multidrug resistance via activating ERK pathway in gastric cancer.

Author information

1
Department of Radiotherapy, Huaihe Hospital of Henan University, Kaifeng 475000, PR China. Electronic address: zhz_7607@126.com.
2
Department of Radiotherapy, Huaihe Hospital of Henan University, Kaifeng 475000, PR China.

Abstract

Multidrug resistance (MDR) is a critical reason of cancer chemotherapy failure. Ribophorin II (RPN2) has emerged as a vital regulator of MDR in multiple cancers including gastric cancer (GC). However, the roles and molecular mechanisms of RPN2 in MDR have not been well featured till now. The present study aimed to explore the roles and molecular mechanisms of RPN2 in MDR of drug-resistant GC cells. Results showed that the expressions of RPN2, multidrug resistance 1 (MDR1), and ATP binding cassette subfamily G member 2 (ABCG2) were upregulated in SGC7901/DDP and SGC7901/VCR cells. Knockdown of RPN2 alleviated MDR through downregulating MDR1 and ABCG2 expressions in SGC7901/DDP and SGC7901/VCR cells. RPN2 depletion inhibited the activation of MEK/ERK pathway. RPN2 overexpression enhanced MDR by upregulating P-glycoprotein (P-gp) and ABCG2 protein expressions in SGC7901/DDP or SGC7901/VCR cells, while this effect of RPN2 was abrogated by ERK knockdown or treatment with ERK inhibitor PD98059. Our findings suggested that RPN2 potentiated P-gp- and ABCG2-mediated MDR via activating MEK/ERK pathway in GC, hinting the critical values of RPN2 in ameliorating MDR and providing a promising target for GC therapy.

KEYWORDS:

ABCG2; Gastric cancer; MDR1; MEK/ERK pathway; Multidrug resistance; Ribophorin II

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center